Polymyxins bind to the cell surface of unculturable Acinetobacter baumannii and cause unique dependent resistance by Zhu, Yan et al.
FULL PAPER
www.advancedscience.com
Polymyxins Bind to the Cell Surface of Unculturable
Acinetobacter baumannii and Cause Unique Dependent
Resistance
Yan Zhu, Jing Lu, Mei-Ling Han, Xukai Jiang, Mohammad A. K. Azad, Nitin A. Patil,
Yu-Wei Lin, Jinxin Zhao, Yang Hu, Heidi H. Yu, Ke Chen, John D. Boyce, Rhys A. Dunstan,
Trevor Lithgow, Christopher K. Barlow, Weifeng Li, Elena K. Schneider-Futschik,
Jiping Wang, Bin Gong, Bjorn Sommer, Darren J. Creek, Jing Fu, Lushan Wang,
Falk Schreiber, Tony Velkov, and Jian Li*
Multidrug-resistant Acinetobacter baumannii is a top-priority pathogen
globally and polymyxins are a last-line therapy. Polymyxin dependence in A.
baumannii (i.e., nonculturable on agar without polymyxins) is a unique and
highly-resistant phenotype with a significant potential to cause treatment
failure in patients. The present study discovers that a polymyxin-dependent A.
baumannii strain possesses mutations in both lpxC (lipopolysaccharide
biosynthesis) and katG (reactive oxygen species scavenging) genes.
Correlative multiomics analyses show a significantly remodeled cell envelope
and remarkably abundant phosphatidylglycerol in the outer membrane (OM).
Molecular dynamics simulations and quantitative membrane lipidomics
reveal that polymyxin-dependent growth emerges only when the
lipopolysaccharide-deficient OM distinctively remodels with ≥ 35%
phosphatidylglycerol, and with “patch” binding on the OM by the rigid
polymyxin molecules containing strong intramolecular hydrogen bonding.
Rather than damaging the OM, polymyxins bind to the
phosphatidylglycerol-rich OM and strengthen the membrane integrity, thereby
protecting bacteria from external reactive oxygen species. Dependent growth
is observed exclusively with polymyxin analogues, indicating a critical role of
the specific amino acid sequence of polymyxins in forming unique structures
for patch-binding to bacterial OM. Polymyxin dependence is a novel antibiotic
resistance mechanism and the current findings highlight the risk of ‘invisible’
polymyxin-dependent isolates in the evolution of resistance.
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The catalase-positive, Gram-negative oppor-
tunistic pathogen Acinetobacter baumannii
causes life-threatening nosocomial in-
fections (e.g., pneumonia, sepsis, and
meningitis) worldwide.[1] A. baumannii
infections are notoriously difficult to treat
due to its extraordinary ability to evolve
multidrug-resistance (MDR).[1,2] Polymyx-
ins (i.e., polymyxin B and colistin) are a
group of cationic lipopeptide antibiotics
and often used as a last-line therapy against
MDR Gram-negative bacteria, including
A. baumannii.[3,4] The exact mechanism of
antibacterial killing by polymyxins remains
unclear; however, the initial step involves
electrostatic interactions between the l-
2,4-diaminobutyric acid (Dab) groups of
the polymyxin molecule and the 1- and 4′-
phosphate groups of lipid A in the bacterial
outer membrane (OM).[5,6] Subsequently,
the fatty acyl tails of polymyxins insert
into the outer leaflet of the bacterial OM,
resulting in membrane disorganization,
cellular content leakage, and eventually cell
death.[5,6] Alternative killing mechanisms
of polymyxins include the inhibition of
type II NADH-quinone oxidoreductase
and the generation of cytotoxic reactive oxygen species (ROS).[7,8]
Resistance to polymyxins can emerge in A. baumannii during
monotherapy and involves lipid A modifications with phospho-
ethanolamine (pEtN),[9] or lipopolysaccharide (LPS) loss.[10–13]
LPS loss causes significant OM remodeling, and is mediated by
mutations in lpxACD, the first three genes of lipid A biosynthe-
sis pathway.[12,13] Surprisingly, certain LPS-deficient A. bauman-
nii strains exhibit not merely a high-level resistance to polymyx-
ins, but also growth dependence on polymyxins, i.e., that bac-
teria only grow proximal to polymyxin-containing discs on agar
plates.[14] However, not all the LPS-loss strains are polymyxin
dependent,[12–14] indicating that LPS deficiency is insufficient for
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polymyxin dependence and other factors exist. Unfortunately, the
current literature on the phospholipid composition of bacterial
membranes in general is very sparse.
Polymyxin-dependent resistance was reported only in Acine-
tobacter species thus far in the clinic.[14–16] A recent clinical
study of 45 patients undergoing colistin treatment showed that
40% A. baumannii isolates acquired colistin dependence and
caused treatment failure; furthermore, after exposure to col-
istin in vitro, 32.9% of 149 colistin-susceptible A. bauman-
nii clinical isolates developed colistin-dependent phenotype.[17]
Culturing A. baumannii in the presence of polymyxins is not
routinely conducted in clinical microbiology diagnostic labora-
tories; therefore, polymyxin-dependent resistant A. baumannii
cannot be easily detected in the absence of polymyxins and
represents a neglected and dangerous clinical issue. Here, we
demonstrated that polymyxin-dependent A. baumannii isolates
were able to cause infection in mice. Using a model strain A.
baumannii AB5075 (also a virulent MDR clinical isolate)[18] and
its polymyxin-dependent mutant 5075D, our correlative systems
pharmacological results and molecular dynamics simulations re-
vealed that polymyxin-dependent resistance in A. baumannii re-
quired at least four factors, LPS loss, distinctive phosphatidyl-
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glycerol (PG) rich OM, rigid polymyxin molecular structure, and
polymyxin binding to the PG-rich OM like ‘patches’.
2. Results
2.1. Characterization of Polymyxin Dependence
A colistin-dependent isolate 5075D was evolved from the wild-
type A. baumannii AB5075 (labeled as 5075S below, see the Exper-
imental Section). Compared to colistin-susceptible 5075S (min-
imum inhibitory concentration [MIC] = 0.25 mg L−1), strain
5075D was highly resistant to colistin (MIC > 128 mg L−1), but
much more susceptible to rifampicin, meropenem, 𝛽-lactams,
and hydrogen peroxide (H2O2) (Table S1, Supporting Informa-
tion). A colistin-resistant mutant 5075R (MIC = 16 mg L−1) was
also obtained, showing a similar susceptibility profile to other
antibiotics as 5075S. When grown on Mueller–Hinton (MH)
agar, 5075R showed a much smaller colistin inhibition zone than
5075S, while 5075D distinguished itself from normal polymyxin-
resistant phenotype by exhibiting a luxuriant growth around the
disc containing 3 µg colistin (Figure 1A). In MH broth, addition
of colistin at concentrations ranging from 2 to 64 mg L−1 sig-
nificantly improved the growth of 5075D (Figure 1B). Interest-
ingly, addition of polymyxins slightly increased the resistance of
5075D to tetracycline. We measured the MICs of tetracycline in
the absence and presence of polymyxin B nonapeptide (PMBN),
respectively. Without PMBN, the MIC of tetracycline against
5075D was 0.0625 mg L−1; whereas with 2–64 mg L−1 PMBN, the
MIC of tetracycline was increased to 0.125–0.25 mg L−1. FADDI-
043 is a dansyl-polymyxin probe and was used for measuring
polymyxin-LPS binding interactions.[19] Compared to 5075S and
5075R, much more FADDI-043 bound to 5075D as shown by
fluorescence-activated cell sorting (FACS) (Figure 1C). Compared
to 5075S, 5075D displayed more severe membrane depolariza-
tion (Figure 1D), reduced metabolic activity (Figure 1E), and
higher oxidative stress in the absence of colistin (Figure 1F). In-
terestingly, addition of 3 mg L−1 colistin to the culture remarkably
restored the metabolic activity and reduced the oxidative stress in
5075D (Figure 1E,F). Further examination using scanning elec-
tron microscopy (SEM) showed, after colistin treatment, bleb-
bing cell surface in 5075S but no significant cell surface changes
in 5075R or 5075D (Figure 1G). Despite attenuated virulence,
5075D was able to cause infection in the thighs of neutropenic
mice and persisted after colistin treatment (90 mg kg−1) for at
least 24 h (Figure 1H).
Whole genome sequencing and Sanger sequencing iden-
tified spontaneous mutations in 5075R and 5075D (Table
S2, Supporting Information). Strain 5075R possessed 3 non-
synonymous substitutions (pmrBG315D, ABUW_0507A91P, and
rpoBF915L), while 5075D had an integration of ISAba1 (1180-bp
in length) at nucleotide position 395 of lpxC (Figures S1 and 2A,
Supporting Information) and 4 nonsynonymous substitutions
(ABUW_0135S25Stop, mrcAM129T, katGR609G, and rpoBF915L). These
changes were present in 100% of reads, making the involvement
of heterogeneity unlikely. ABUW_0135 encodes a putative
signaling protein with unknown function, while mrcA encodes
penicillin-binding protein 1A and its inactivation could promote
LPS loss in A. baumannii.[20] The mutants with a single T26
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Figure 1. Phenotypic analyses of polymyxin-dependent growth. A) 5075S, 5075R, and 5075D grown on MH agar with 3 µg colistin discs. Viable counting
showed 1.9 × 106 Colony Forming Unit (CFU) mL−1 cells for both 5075S and 5075R, and 3.3 × 105 CFU mL−1 cells for 5075D. B) 5075D growth in MH
broth with 0–128 mg L−1 colistin (n = 4). Data are shown as mean ± SD. C) Increased uptake of dansyl-polymyxin probe FADDI-043 in 5075D compared
to 5075S and 5075R. D) Membrane depolarization of 5075D relative to 5075S with and without colistin treatment. DiBAC, bis-(1,3-dibutylbarbituric
acid)trimethine oxonol. E) Metabolic activity of 5075D was lower than the wild-type 5075S without colistin, but was restored in the presence of colistin.
F) Enhanced oxidative stress in 5075D relative to 5075S with and without colistin treatment. G) SEM images of 5075S, 5075R, and 5075D in the absence
and presence of colistin. H) In vivo bacterial burden of 5075S (n = 6), 5075R (n = 4), and 5075D (n = 6) with or without colistin treatment. Data are
shown as mean ± SD.
transposon insertion in ABUW_0135, mrcA, katG, and rpoB were
all susceptible to polymyxins (MIC ≤ 1 mg L−1, Tables S1 and S2,
Supporting Information), indicating that the inactivation of these
individual genes did not confer polymyxin-dependent resistance.
lpxC encodes UDP-3-O-acyl-N-acetylglucosamine deacetylase
that catalyzes the second reaction in lipid A biosynthesis.[13]
Our previous study showed that IS insertions in lpxC abol-
ished its function, led to LPS loss and high-level resistance to
polymyxins.[13] katG encodes a catalase and A. baumannii lacking
katG showed increased susceptibility to H2O2.
[21] Interestingly,
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Figure 2. Insertional-inactivated lpxC in 5075D and complementation. A)
ISAba1 insertion in lpxC of 5075D. B) Disc diffusion assay of 5075D, 5075D
with an empty vector, katG complementation, and lpxC complementation
strains.
the complementation of lpxC completely eliminated polymyxin
resistance and dependence, and restored the susceptibility,
while the complementation of katG partially reduced polymyxin
dependence (Figure 2B). Taken together, the lpxC mutation was
essential in the acquisition of polymyxin dependence in 5075D,
while the katG mutation is not essential but played an important
role here.
2.2. Integrative Analysis of Multiomics
To understand the mechanism of polymyxin dependence, cor-
relative transcriptomics and metabolomics were conducted,
and outer membrane proteomics was performed to support
the transcriptomics results. Overall, the global gene expression
and abundance of whole-cell metabolites in 5075D were signif-
icantly different from those in 5075S and 5075R, and several
interesting outer membrane proteins (OMPs) were evident in
the proteomics results of 5075D; whereas colistin treatment
resulted in profound changes in the metabolite and OMP abun-
dance of 5075D. No common differentially expressed gene or
altered metabolite was identified in 5075S, 5075R, and 5075D in
response to 20 h colistin treatment (Figures S2A,B, S3A–C, and
Datasets S1–S3, Supporting Information).
Polymyxin resistance in A. baumannii can be mediated by lipid
A modification.[10,11] In 5075S, 20 h colistin treatment caused 2.3-
fold increase in the expression of lipid A phosphoethanolamine
transferase gene pmrC. In the absence of colistin, the expression
of pmrC was 3.2-fold higher in 5075R than that in 5075S. Inter-
estingly, without colistin treatment lpxC was downregulated by
2.6-fold in 5075R relative to 5075S, but remained unchanged in
5075S and 5075R when exposed to colistin treatments (Figure 3).
Compared to untreated 5075S, several key genes related to the
OM phospholipid biosynthesis and transport were differentially
expressed in the untreated 5075D, including i) increased expres-
sion of gpsA (glycerol 3-phosphate dehydrogenase, 1.8-fold), glpK
(glycerol kinase, 2.1-fold), mlaD (OM lipid asymmetry mainte-
nance protein, an component of the phospholipid retrograde
transport system, 1.7-fold) and pgpB (phosphatidylglycerophos-
phate phosphatase B, 1.7-fold), and ii) decreased expression
of pldA (phospholipase A, 2.0-fold) (Figure 3). Metabolomics
analysis showed significantly changed levels of phospholipids in
untreated 5075D compared to untreated 5075S (Figure S3A,B,
Supporting Information). Collectively, both transcriptomic and
metabolomics results indicate increased phospholipid biosyn-
thesis and perturbed phospholipid turnover in 5075D. Notably,
compared to the untreated 5075S, the untreated 5075D signifi-
cantly increased the expression of accB and fabDGI (Figure 3), as
well as elevated the levels of fatty acids (Figure S3A,B, Supporting
Information), indicating increased fatty acid biosynthesis for the
substantial OM remodeling due to LPS loss. It should be noted
that in 5075D, 20 h colistin treatment resulted in a remarkable
increase (2.2- to 4.8-fold) of 77 fatty acids and fatty acid deriva-
tives, but no significant changes in the gene expression (Figure
S3A–C and Datasets S1 and S2, Supporting Information).
The peptidoglycan recycling genes were exclusively up-
regulated in untreated 5075D compared to untreated 5075S
(Figure 3). Consistently, the accumulation of N-acetyl-d-
glucosamine(anhydrous)N-acetylmuramoyl-l-Ala-d-Glu-meso-
2,6-diaminopimelate and depletion of UDP-N-acetylmuramoyl-l-
Ala-d-Glu-meso-2,6-diaminopimeloyl-d-Ala-d-Ala were observed
only in untreated 5075D, indicating an active peptidoglycan re-
cycling and biosynthesis most likely due to the OM remodeling.
Additionally, the expression of poly-𝛽-1,6-N-acetylglucosamine
biosynthesis and transport genes pgaABCD was significantly
downregulated by 4.7- to 6.6-fold in untreated 5075R and
5075D, compared to the untreated 5075S (Figure S4, Supporting
Information).
A number of upregulated genes and depleted metabolites were
exclusively observed in 5075D in the absence of colistin treat-
ment, compared to 5075S, including those from tricarboxylic acid
cycle, gluconeogenesis, energy generation, efflux pumps, and
biosynthesis of nucleotides, arginine, methionine, and cysteine
(Figure S4, Supporting Information). The expression of several
ribosomal and aminoacyl-tRNA synthetase genes was increased
in untreated 5075D, compared to untreated 5075S, indicating an
enhanced translation activity (Figure S4 and Dataset S1, Sup-
porting Information). Compared to 5075S, 5075D was under a
higher level of oxidative stress in the absence of colistin (Fig-
ure 1F). A number of genes associated with oxidative stress re-
sponses were differentially expressed in untreated 5075D com-
pared to untreated 5075S, including the reduced expression of
ferric uptake repressor fur and the increased expression of genes
related to siderophore synthesis and transport, heme genera-
tion, glutathione biosynthesis, sulfate uptake and assimilation,
and thiol/disulfide homeostasis maintenance (Figure S4, Sup-
porting Information); all these results indicated a defense against
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Figure 3. Transcriptomic, metabolomic, and OM proteomic analyses show the significantly perturbed membrane biogenesis by either genetic vari-
ations or colistin treatment. AcCoA, acetyl-CoA; anhgm3p, N-acetyl-D-glucosamine(anhydrous)N-acetylmuramyl-l-Ala-d-Glu-meso-diaminopimelate;
anhMurNAc, 1,6-anhydro-N-acetylmuramic acid; CMP-KDO, CMP-3-deoxy-d-manno-octulosonate; DHAP, dihydroxyacetone phosphate; F6P, D-fructose
6-phosphate; G3P, glyceraldehyde 3-phosphate; GlcN-1-P, D-glucosamine 1-phosphate; GlcN-6-P, D-glucosamine 6-phosphate; Glyc, glycerol; Glyc3P,
glycerol 3-phosphate; PGP, phosphatidylglycerol-phosphate; PS, phosphatidylserine; UDCPDP, undecaprenyl diphosphate; UDP-GlcNAc, UDP-N-
acetyl-d-glucosamine; UGMD, UDP-N-acetylmuramoyl-l-Ala-d-Glu-meso-2,6-diaminopimelate; UGMDA, UDP-N-acetylmuramoyl-l-Ala-D-Glu-meso-2,6-
diaminopimeloyl-d-Ala-d-Ala. The genes, metabolites, and proteins explicitly referred are shown in black background.
aggravated oxidative stress in 5075D, which was due to the loss
of LPS and KatG malfunction in particular.
2.3. Outer Membrane Remodeling
The correlative multiomics results above indicated that the OM
of 5075D was substantially remodeled due to LPS loss. There-
fore, we conducted lipid A profiling and quantitative membrane
lipidomics with 5075S, 5075R, and 5075D. Lipid A profiling
showed that both 5075S and 5075R produced LPS, while LPS
was absent in 5075D but restored by lpxC complementation
(Figure 4A). Specifically, both hexa-acylated (m/z 1632.15 and
1648.15) and hepta-acylated (m/z 1814.32, 1830.32, 1870.38, and
1886.38) lipid A species were present in 5075S (Figure 4A). After
20 h colistin treatment, a small proportion of pEtN modification
at 1- or 4′-phosphate was observed at m/z 1953.32 in 5075S (Fig-
ure S5, Supporting Information). In 5075R, the pEtN-modified
hexa- (m/z 1755.16 and 1771.16) and hepta-acylated (m/z 1937.33
and 1953.32) lipid A species were dominant, regardless of colistin
treatment (Figure 4A; and Figure S5, Supporting Information).
In 5075D, lipid A was depleted (in the absence and presence of
colistin) but restored by lpxC complementation (Figure 4A; and
Figure S5, Supporting Information).
As LPS is predominant in the outer leaflet of Gram-negative
bacterial OM,[22] its depletion causes significant OM re-
modeling with increased abundances of phospholipids and
lipoproteins.[23,24] We therefore quantified the OM phospholipid
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Figure 4. LPS depletion and significant changes of membrane phospholipids in 5075D. A) Lipid A profiles of 5075S, 5075R, 5075D, and 5075D pWH1266-
lpxC with putative lipid A structures. The m/z values of unmodified, modified, newly emerged unmodified (after lpxC complementation) lipid A are indi-
cated in red, blue, and green, respectively. B) Membrane phospholipid compositions in different A. baumannii strains, including katG (5075D pWH1266-
katG) and lpxC (5075D pWH1266-lpxC) complementation strains (n = 2). Data are shown as mean values.
abundances (Experimental Section, Supporting Information)
and our results (Figure 4B; and Dataset S4, Supporting In-
formation) demonstrated that phosphatidylethanolamine (PE)
accounted for the majority (57.7–71.0%) of the total OM phos-
pholipids in 5075S and 5075R, while its proportion was strikingly
lower in 5075D (37.4% and 34.2% in the absence and presence
of colistin, respectively) (Figure 4B; and Dataset S4, Supporting
Information). Surprisingly, the PG content in OM phospholipids
of 5075D was remarkably higher (46.7% and 51.7% in the
absence and presence of colistin, respectively) than in 5075S
and 5075R (16.5–29.1% with and without colistin, Figure 4B).
Whereas the phospholipid composition of the IM remained
largely unchanged in all three isolates regardless of colistin
treatment (Figure 4B). Inactivation of PG biosynthesis genes
PG phosphatase A (pgpA) or B (pgpB) significantly increased the
susceptibility to colistin, which is indicated by drastically reduced
viable cells of AB00256 (pgpA::T26, 6.6 × 102 CFU mL−1) and
AB08847 (pgpB::T26, 8.9 × 102 CFU mL−1) compared to 5075S
(2.1 × 1010 CFU/mL−1) after 4 mg L−1 colistin treatment for 24 h.
These results showed a critical role of PG in developing colistin
resistance in A. baumannii. Complementation of katG in 5075D
resulted in significant increase of PE (up to 54.0% from 37.4% in
untreated 5075D) and decrease of PG (down to 36.0% from 46.7%
in untreated 5075D) in the OM, consistent with the partial loss
of polymyxin dependence as shown in Figure 2B. This suggested
that the OM remodeling in 5075D was partially induced by the
oxidative stress due to the katG mutation. Whereas the com-
plementation of lpxC restored the OM phospholipid com-
position similar to the levels in wild-type 5075S with the
proportions of PE and PG to 67.2% and 19.4%, respectively
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Figure 5. Molecular dynamics simulations show a patch binding of polymyxins to the OM of 5075D. A) Molecular interactions between colistin (violet)
and phospholipid molecules in the outer leaflet of 5075D OM. The colistin-interacting PG, PE, and CL are indicated in orange, green, and dark blue,
respectively; while the noninteracting phospholipids in the outer and inner leaflets of OM are indicated in gray and light blue, respectively. The H-
bonds within colistin molecule and between colistin and phospholipid molecules are indicated by green and yellow dashed lines, respectively. B) The
hydrophobic and electrostatic interaction energy of the fatty acyl tail and each amino acid residue of colistin. Interaction energy error bars were calculated
using the block averaging method. C) The average number of H-bonds between each colistin Dab residue and phospholipids. D) Binding of colistin
or PMBN to the OM significantly reduced the overall membrane lateral diffusion coefficient in 5075D. Colistin and PMBN molecules are shown in
violet. Color-coding from blue to red indicates the phospholipids with low to high membrane lateral diffusion coefficient (LDC). E) Relative change of
LDC with and without colistin at each specific PG proportion (20–50%), calculated by (LDCcolistin – LDCcontrol)/LDCcontrol × 100%. Averaged LDC (n = 2
membranes) was calculated for 5075D. F) The averaged total number of phospholipids forming H-bonds with colistin molecules at each specific PG
proportion (20–50%). G) The composition of H-bonds formed with different phospholipids at each specific proportion of PG (20–50%) in the OM.
(Figure 4B). To test whether LPS deficiency would be suffi-
cient to cause polymyxin dependence, we examined another
LPS-deficient, polymyxin-resistant strain 19606R (colistin MIC
> 128 mg L−1) derived from the wild-type A. baumannii ATCC
19606 (colistin MIC = 0.5 mg L−1).[12] Interestingly, 19606R
showed no polymyxin dependence, and PE and PG in its
OM accounted for 64.1% and 26.2%, respectively (Figure 4B).
Taken together, these results showed, for the first time, that
LPS loss causes polymyxin resistance, but not necessarily
polymyxin dependence; while a high PG proportion in the LPS-
deficient OM is essential for polymyxin-dependent resistance in
A. baumannii.
2.4. Colistin Physically Stabilized 5075D OM
Our multiomics results indicated that the unique OM composi-
tion played an essential role in polymyxin dependence; therefore,
molecular dynamics simulations were conducted based upon
our OM lipidomics results above (Figure 4B). Very interestingly,
colistin uniquely bound to different phospholipids in the PG-
rich outer leaflet of the 5075D OM (Figure 5A). The cyclic head
of colistin molecule interacted with the surrounding phospho-
lipid head groups in the LPS-deficient 5075D OM in a patch
binding manner (Movie S1, Supporting Information). On av-
erage, each colistin molecule interacted with 5.75 neighboring
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phospholipids and formed 12.25 hydrogen bonds (H-bonds)
therewith. For each colistin molecule, on average the five cationic
Dab residues (i.e., Dab1, Dab3, Dab5, Dab8, and Dab9) interacted
with the head groups of 3.40 PG, 1.20 PE, and 0.80 cardiolipin
(CL), which contributed 69.7% of the total interaction energy
(Figure 5B). Specifically, each colistin Dab residue formed 1.25–
2.75 H-bonds with phospholipids and Dab3 formed the maxi-
mum number of H-bonds (Figure 5C). Among all the H-bonds
between colistin Dab residues and phospholipids in the outer
leaflet of bacterial OM, 62.6% were formed with PG, even though
PG only accounted for 46.7% of the OM phospholipids in 5075D
(Figure 5C). Notably, Dab5, Dab8, and Dab9 were prone to form
H-bonds with PG; Dab1 formed H-bonds only with PG; Dab3
formed H-bonds equally with PE and PG (Figure 5C). Addition-
ally, 5.0 H-bonds were formed within a colistin molecule on av-
erage (Figure 5A). Upon colistin binding, the neighboring phos-
pholipids were constrained, leading to limited movement of the
phospholipids and a significantly declined lateral diffusion coeffi-
cient (from 4.35× 10−8 cm2 s−1 to 2.92× 10−8 cm2 s−1; Figure 5D),
which supports the patch binding mode by colistin on the LPS-
deficient OM of 5075D. In 5075S OM, the lateral diffusion coef-
ficient was 1.08 × 10−8 cm2 s−1. Further simulations with PMBN
(derived by cleavage of the fatty acyl tail and Dab1 residue from
polymyxin B) showed that PMBN also patch bound to 5075D OM
and reduced the lateral diffusion coefficient to 3.24× 10−8 cm2 s−1
(Figure 5D; and Movie S2, Supporting Information); these results
showed that the polymyxin Dab residues (in particular Dab3,
Dab5, Dab8, and Dab9) played major roles in membrane stabi-
lization.
To test our hypothesis on the essentiality of unique PG com-
position in the OM for polymyxin dependence, we conducted a
series of simulations with the OM PG composition varying from
20% to 50%. Excitingly, the results confirmed that colistin bind-
ing did not decrease membrane lateral diffusion until the PG con-
tent in the outer leaflet of the LPS-deficient OM reached ≈35%
and above (Figure 5E); and importantly, only when the PG com-
position was above this threshold, colistin molecules were able
to uniquely patch bind to the OM via interacting more favorably
with PG than PE and CL (Figure 5F,G). Therefore, LPS-deficient
strain 19606R with a low-PG OM (26.2%, Figure 4B) showed
only polymyxin resistance but no dependence. Collectively, our
results reveal that a unique PG proportion in the outer leaflet of
5075D OM is essential to the patch binding of polymyxins via
the Dab residues, which leads to the stabilization of the OM and
polymyxin dependence.
2.5. A Rigid Molecular Structure of Polymyxins is Essential for
the Dependent Resistance
It is unknown if the specific amino acid sequence and the ring
structure of polymyxins or other polycationic peptides are es-
sential for the dependent resistance. Therefore, we employed
a chemical biology approach and further examined the depen-
dence of strain 5075D in the presence of 7 different peptides:
linear polymyxin B1, antimicrobial peptide LL-37, polymyxin
B1(Lys-1, 3, 5, 8, 9), linear poly-l-arginine (RRRRRR), lin-
ear poly-l-lysine (KKKKKK), cyclic poly-l-arginine (RRRRRR),
and cyclic poly-l-lysine (KKKKKK); the last two cyclic peptides
represente a similar size of the polycationic ring as polymyx-
ins. Notably, dependence was observed only in the presence of
linear polymyxin B1 and polymyxin B1(Lys-1, 3, 5, 8, 9), but
not the other five peptides (Figure S6A, Supporting Informa-
tion). Our results demonstrated that polymyxin dependence re-
quired a specific amino acid sequence, but not necessarily a cyclic
structure.
Subsequently, molecular dynamics simulations were con-
ducted to elucidate the mechanism of the interaction between
5075D OM and linear polymyxin B1 or linear poly-l-arginine.
Similar to colistin and polymyxin B nonapeptide, linear
polymyxin B1 significantly decreased the membrane lateral
diffusion from 4.35 × 10−8 cm2 s−1 to 2.60 × 10−8 cm2 s−1
(Figure S6B, Supporting Information), suggesting that linear
polymyxin B1 was also able to stabilize LPS-deficient 5075D
OM. Whereas the membrane lateral diffusion was increased
from 4.35 × 10−8 cm2 s−1 to 5.58 × 10−8 cm2 s−1 (Figure S6C,
Supporting Information) in the presence of poly-l-arginine,
which is consistent with disc diffusion assay results (Figure S6A,
Supporting Information). Notably, both linear polymyxin B1 and
poly-l-arginine molecules could electrostatically interact with
6.5 membrane phospholipids (0.75 PE, 4.75 PG, and 1.00 CL for
linear polymyxin B1; 2.00 PE, 3.25 PG, and 1.25 CL for poly-l-
arginine) via 17.25 and 16.5 H-bonds, respectively; however, the
intramolecular electrostatic interactions were prominent in lin-
ear polymyxin B1 (4.75 H-bonds formed per peptide molecule)
than linear poly-l-arginine (1.0 H-bonds formed per peptide
molecule). Establishing a strong intramolecular polar interac-
tion potentially increased the molecular rigidity of polymyxins
during their interaction with bacterial OM, thereby stabilizing
the LPS-deficient OM and conferring polymyxin dependence.
3. Discussion
Polymyxin dependence is a unique resistance phenotype
and has been overlooked in the clinic, as such isolates are
nonculturable on conventional bacteriological agar plates
in the absence of polymyxins. Antibiotic dependence has
been reported in vancomycin-resistant Enterococcus, linezolid-
resistant Staphylococcus epidermidis, and 𝛽-lactam-resistant S.
aureus.[25–27] However, these Gram-positive bacteria either re-
quire antibiotic-mediated gene induction to complement their
functional defects,[25,27,28] or display a functional adaptation
to the antibiotic.[26] In our preliminary experiments, we also
explored if polymyxin dependence exists in other Gram-negative
bacteria (e.g., Pseudomonas aeruginosa and Klebsiella pneumo-
niae); however, no single polymyxin-dependent strain could be
selected in either species. As lipid A is essential for bacterial
viability in P. aeruginosa and K. pneumoniae, lipid A modifica-
tions in polymyxin-resistant strains do not cause dramatic OM
remodeling, such as significant increase of PG component in
the OM. Vancomycin-resistant Enterococcus obligatorily requires
continuous exposure to vancomycin for growth; intriguingly,
polymyxin-dependent A. baumannii can survive both in vitro and
in vivo in the absence of polymyxins, even it is nonculturable
on normal agar plates (Figure 1B–H). Indeed, clinical studies
have shown a high rate of polymyxin dependence in polymyxin-
resistant Acinetobacter clinical isolates and higher rates of
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treatment failure in patients.[17] Therefore, the probability of
nosocomial transmission of polymyxin-dependent resistant A.
baumannii has been substantially under-estimated.[27,28]
Our results show that LPS loss is essential but only the first
step of acquiring polymyxin-dependent resistance. The signifi-
cant changes related to the OM remodeling in 5075D (e.g., per-
turbed phospholipid biogenesis and increased fatty acid biosyn-
thesis, lipoprotein transport, and peptidoglycan recycling; Fig-
ure 3) are consistent with previous transcriptomics results from
LPS-deficient A. baumannii.[20,29] The upregulated genes related
to sulfur homeostasis and ferric utilization indicated severe ox-
idative stress in 5075D due to the katG mutation (Figure S4, Sup-
porting Information). A very recent study discovered that the lytic
transglycosylase gene mltF (ACICU_0 2898) could contribute to
polymyxin dependence in A. baumannii.[30] Its homologs (HM-
PREF0010_0 2077 in ATCC 19606, ABUW_0928 in AB5075)
were also transcriptionally upregulated in untreated 19606R com-
pared to untreated ATCC 19606,[23] and in untreated 5075D com-
pared to untreated 5075S; but remained unchanged in 5075D in
the presence and absence of colistin (Figure 3). Collectively, these
results indicate that mltF might be essential for the survival of
LPS-deficient A. baumannii, but not for polymyxin dependence.
Very limited information in previous literature suggested
that polymyxin dependence was associated with the defects of
lipid A biosynthesis;[14,17,30,31] however, not all LPS-deficient A.
baumannii isolates are polymyxin-dependent (e.g., 19606R).
A major finding of our study is that, besides the significantly
remodeled OM due to LPS loss, the combination of another
two factors is key for polymyxin dependence: i) a uniquely high
proportion of PG in the OM (≥ 35%), and ii) cytotoxic ROS that
was harmful due to the instability of the remodeled OM. Bacteria
need meticulous regulation of their membrane phospholipid
composition, in particular maintaining an appropriate ratio
between zwitterionic phospholipids (e.g., PE) and anionic phos-
pholipids (e.g., PG) to achieve an optimal membrane stability.[32]
In Gram-negative bacterial OM, anionic PG normally accounts
for < 30%.[33] In polymyxin-resistant, LPS-deficient 19606R,
the PG proportion in the OM was 26.2%; however, the PG
proportion surprisingly increased to ≥35% in the polymyxin-
dependent A. baumannii strains (46.7% in 5075D and 36.0% in
5075D-pWH1266:katG, see Figure 4). The proposed mechanism
of polymyxin dependence was also discovered in at least another
two A. baumannii strains FADDI-AB018D (sequence type [ST]
2) and FADDI-AB046D (ST1). Both strains exhibited deficiency
of LPS due to loss-of-function mutations in lipid A biosynthesis
genes (lpxAA141V for FADDI-AB018D and lpxCG35Stop for FADDI-
AB046D), and a high molar proportion (>35%) of PG in the
LPS-deficient OM.[34] To the best of our knowledge, this is the first
set of quantitative membrane lipidomics data showing a high
proportion of PG in the OM of Gram-negative bacteria, which
provides novel mechanistic information on the OM remodeling.
Our molecular dynamics simulation results showed that the
PG-rich OM of 5075D was much less stable; its lateral diffusion
(4.35 × 10−8 cm2 s−1) was fourfold higher than that in 5075S
(1.08 × 10−8 cm2 s−1) and 15-fold higher than the reported value
in E. coli (0.29 × 10−8 cm2 s−1).[35] In addition, our FACS results
showed a significantly reduced metabolic activity in 5075D com-
pared to 5075S without colistin (Figure 1E). When the proportion
of PG in the OM increased, the intermolecular electrostatic
repulsion between the negatively-charged PG head groups
became profound and the positively-charged molecules on
membrane surface were able to stabilize its structure. Indeed,
the surface patch binding of polymyxin “band-aid” stabilized the
remodeled LPS-deficient PG-rich OM (Figure 5D), thereby pro-
tecting bacterial cells from the ROS damage (Figures 1F and 6)
and restored metabolic activity (Figure 1E). As polymyxins bind
to PG more favorably than PE (Figure 5C), such patch binding
occurs only when the PG proportion in the OM is sufficiently
high (≥ 35%, Figure 5E), wherein polymyxin molecules are
able to form three or more H-bonds with PG, a tripod-like
configuration to stabilize the LPS-deficient OM (Figure 5F,G).
The MD results of linear polymyxin B1 demonstrated that the
rigid molecular structure via forming multiple intramolecular
H-bonds played a key role in stabilizing LPS-deficient bacterial
OM (Figure S6B,C, Supporting Information). In terms of the
OM phospholipid composition, disruption of PG biosynthesis
genes (pgpAB) caused significantly increased susceptibility
to colistin (≈8-log10 reduction of the number of viable cells
compared to that in 5075S after 4 mg L−1 colistin treatment for
24 h). Our experimental and molecular dynamics simulation
results (Figure 5E) also revealed that LPS-deficient A. bauman-
nii 19606R (a mutant derived from ATCC 19606) was only
polymyxin-resistant, but not dependent, as the PG content in its
OM was too low to form sufficient phospholipid ‘rafts’ (26.2%,
Figure 4B) enabling the surface patch binding of polymyxins.
Consistently, our experimental results with the katG mutant and
its complemented strain (5075D pWH1266-katG) demonstrated
that polymyxin dependence emerged (Figure 2B) in the katG
mutant (PG = 36.0%, Figure 4B), which well supported our
MD simulation results on the PG composition threshold for
polymyxin dependence (≥35%). Furthermore, both experimental
and molecular dynamics simulation results demonstrated that
the fatty acyl chain of polymyxins was not essential for polymyxin
dependence, as PMBN also stabilized the LPS-deficient OM in
5075D. In summary, our results demonstrated that polymyxin
dependence did not occur in LPS-deficient A. baumannii, unless
the PG proportion in the outer leaflet of the OM made the patch
binding of polymyxins feasible (Figure 5E–G).
Collectively, our study discovered a novel antibiotic resistance
mechanism, showing how polymyxins stabilize the LPS-deficient
OM of unculturable A. baumannii and lead to resistance to them-
selves. Our integrated multiomics results demonstrated, for the
first time, the significantly increased proportion of PG in the
OM of polymyxin-dependent resistant A. baumannii. Polymyxin-
dependent resistance represents a novel structural and functional
adaptation to antibiotic treatment in this top-priority ‘superbug.’
The emergence of polymyxin-dependent resistance is formidable
and has significant clinical implications, considering that such
dependent isolates are undetectable with current diagnostic pro-
cedures in hospitals and have caused treatment failure in pa-
tients. Our novel mechanistic findings may help optimize antibi-
otic therapies for life-threatening infections caused by MDR A.
baumannii.
4. Experimental Section
Bacterial Strains: A. baumannii strains were grown in MH media
(Oxoid, UK) supplemented with antibiotics where appropriate. To obtain
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Figure 6. Unique surface patch binding of polymyxins stabilizes the remodeled LPS-deficient PG-rich OM and decreases ROS damage in 5075D, com-
pared to 5075S and 5075R. A) 5075S, 5075R, and 5075D grown on MH agar with polymyxin discs. The distal and proximal positions with low and high
concentrations of polymyxin are indicated by blue and red arrows, respectively. B) In polymyxin-susceptible 5075S, external H2O2 molecules barely enter
a cell and are scavenged by KatG catalase. Polymyxins disorganize the OM, significantly increase the influx of H2O2 which in turn saturates KatG. The
extra H2O2 is converted to hydroxyl radical that produces mutagenic and lethal lesions. C) In polymyxin-resistant 5075R, lipid A is modified with pEtN
(red dots). Polymyxins cause less OM damage, and not many H2O2 molecules enter a cell which are scavenged. D) In polymyxin-dependent 5075D, OM
is unstable and leaky due to LPS loss and remodeling, and thus H2O2 molecules easily diffuse into a cell. Owing to KatG dysfunction, a large number
of hydroxyl radicals are generated from H2O2. Polymyxins patch bind to the surface of remodeled, PG-rich OM and stabilize the membrane, thereby
decreasing the H2O2 influx and reducing the generation of hydroxyl radicals. The concentration of polymyxins in the distant area from the polymyxin
disc (indicated by the blue arrows) was insufficient to stabilize the OM of 5075D; therefore, no bacterial growth was evident.
a polymyxin-dependent mutant, 100 µL log-phase bacterial culture and its
serial dilutions were plated on MH agar containing 8 mg L−1 colistin (Be-
taPharma, China). Colonies were subsequently plated on MH agar with a
sterile filter paper disc (8 mm in diameter) containing 3 µg colistin. Bac-
terial colonies that only grew near the disc but not on the rest of the plate
were selected. Transposon insertion mutants were purchased from the
Manoil Laboratory at the University of Washington, and cultured to test
polymyxin susceptibility.[36] Escherichia coli DH5𝛼 (Thermo Fisher Scien-
tific, Waltham, MA) was grown in Luria-Bertani broth supplemented with
appropriate antibiotics. MICs of polymyxins were measured using broth
microdilution methods according to Clinical and Laboratory Standards In-
stitute standards.[37] The susceptibility to other antibiotics was evaluated
using VITEK 2 at Alfred Pathology Service (Alfred Hospital, Melbourne,
Australia).
For complementation, fragments containing the full-length genes and
their native promoters were cloned to pWH1266. Strain 5075D was
transformed with the constructs by electroporation (BioRad, Hercules,
CA).[38] Transformants were selected on MH agar with either 0.75 (katG
complementation) or 5 µg mL−1 (lpxC complementation) tetracycline
(Sigma-Aldrich, USA); 0.75 µg mL−1 tetracycline was used for katG com-
plementation because the transformant was LPS-deficient and highly sus-
ceptible to tetracycline. The complementation was verified by Sanger se-
quencing at Monash Micromon (Clayton, Australia).
Phenotypic Assays: For disc diffusion assay, bacterial colonies were
picked up from MH agar and resuspended in 0.9% w/w saline (McFar-
land = 1, i.e., 3 × 108 CFU mL−1). MH agar plates were inoculated with
1:100 diluted culture using a swab. Sterile discs with 10 µg colistin (Beta
Pharma, China), 10 µg polymyxin B (Beta Pharma, China), 10 µL 0.9% w/w
saline, in-house synthesized polymyxin analogues and peptides (15 µg
polymyxin B nonapeptide, 15 µg linear polymyxin B1, 50 µg LL-37, 15-µg
polymyxin B1(Lys-1, 3, 5, 8, 9), 15 µg linear poly-l-arginine, 15 µg cyclic
poly-l-arginine, 15 µg linear poly-l-lysine, and 15 µg cyclic poly-l-lysine)
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were placed onto agar plates which were incubated at 37 °C for 20 h. For
growth curves,[39] 1 µL of the above-mentioned diluted culture was added
to 99 µL fresh MH broth in the absence and presence of colistin (0.125, 8,
and 64 mg L−1 for 5075S, 5075R, and 5075D, respectively) or/and catalase
(20 U µL−1 for 5075D); real-time optical density changes were recorded
using a plate reader (Tecan, Switzerland). Strain 5075S and transposon
insertion mutants AB00256 (pgpA::T26) and AB08847 (pgpB::T26) were
cultured in cation-adjusted MH broth (CaMHB) in the absence and pres-
ence of 4 mg L−1 colistin for 24 h with an inoculum of 106 CFU mL−1.
Samples were collected at 0 and 24 h and plated on nutrient agar (Oxoid)
for viable counting.
Flow Cytometry Experiments: To investigate the cellular accumulation
of polymyxins, early-log bacterial MH cultures (OD600 0.5) were treated
with 3 mg L−1 fluorescent dansyl-polymyxin probe FADDI-043 for 1 h.[19]
MICs of FADDI-043 for 5075S, 5075R, and 5075D were 2, 2, and 4 mg L−1,
respectively. Cells were pelleted, washed twice and further diluted to
5 × 106 CFU mL−1. Samples were then analyzed by flow cytometry (Novo-
Cyte; ACEA Biosciences, USA) with excitation/emission at 405/530 nm. To
check membrane polarity, metabolic activity, and cellular oxidative stress,
bacteria grown at the edge of inhibition zone around a 3 µg colistin disc
were collected. Specifically, bacterial cultures were directly diluted with
saline to 5 × 106 CFU mL−1, and then stained with 1.6 µg mL−1 bis-
(1,3-dibutylbarbituric acid)trimethine oxonol [DiBAC4(3); Sigma-Aldrich,
St. Louis, MO] or 3.3 µg L−1 ethidium bromide (EtBr, Sigma-Aldrich, St.
Louis, MO) for 1 min. Samples were then analyzed by flow cytometry with
excitation/emission at 488/530 nm [DiBAC4(3)] or 488/675 nm (EtBr).
For oxidative stress, early-log (OD600 = 0.5) cultures were treated with
3 mg L−1 colistin for 1 h with 1.0 × 10−6 m CellRox Green (Thermo Fisher
Scientific).[40] Bacterial cells were pelleted, washed once by saline, and re-
suspended. Samples were then diluted to 5 × 106 CFU mL−1, injected to
the flow cytometer and analyzed with excitation/emission at 488/530 nm.
Microscopy Imaging Experiments: Bacterial early-log (OD600 = 0.5) cul-
tures were treated with colistin (2 mg L−1 for 5075S and 10 mg L−1
for 5075R and 5075D) or saline (control) for 1 h, respectively. Samples
were collected, fixed with 2.5% glutaraldehyde, dehydrated with gradient
ethanol, dried with Leica EM CPD300 (Germany), and imaged with FEI
TeneoVS 3D SEM (FEI, USA).[41]
Neutropenic Murine Thigh Infection Experiment: Animal experiments
were approved by the Monash Animal Ethics Committee (animal ethics
application approval number MARP/2018/011) and animals were main-
tained in accordance with the Australian Code of Practice for the Care and
Use of Animals for Scientific Purposes. Eight-week-old, specific-pathogen-
free, female Swiss mice (24–30 g) were obtained from Monash Animal Ser-
vices (Clayton, Australia) and were fed, housed, and rendered neutropenic
by the administration of cyclophosphamide.[42] Colistin treatment (subcu-
taneous injection of colistin sulfate with 30 mg kg−1 every 8 h) was initi-
ated at 2 h after the inoculation of 105 CFU bacteria (i.e., 5075S, 5075R,
and 5075D) in 50 µL saline. Bacterial burden in thighs was determined at 0
and 24 h after the treatment using MH agar containing 0, 2, and 16 mg L−1
colistin.[42] Sanger sequencing was used to verify lpxC and katG mutations
in samples of 5075D.
Multiomics Experiments: Bacterial cultures grown on Mueller–Hinton
agar with a blank disc (i.e., no colistin) were used as untreated control
samples; for treatment conditions, bacterial cultures were collected from
the edge of the colistin inhibition zone. Bacterial samples were washed
with saline for multiomics studies below. Genomic DNA and total RNA
were extracted using DNeasy Blood and Tissue Kit and RNeasy Mini kit
(QIAGEN, Hilden, Germany) and stored at −80 °C pending sequencing
using Illumina MiSeq.[9] Whole-cell metabolomics samples were prepared
using the previous method.[43] For membrane lipidomics and proteomics,
samples were prepared using sucrose gradient ultracentrifugation and to-
tal protein of each membrane fraction was analyzed by SDS-PAGE with
Coomassie brilliant blue staining.[44] Prior to lipid extraction, membrane
samples were normalized to 2 mg mL−1 by Pierce bicinchoninic acid (BCA)
protein assay (Thermo Fisher Scientific). Membrane lipids were extracted
by a double-phase Bligh-Dyer solution (Experimental Section, Supporting
Information).[45] The OM protein fraction was normalized to 200 µg with
100 mm TRIS buffer, followed by extraction and trypsin digestion. Lipid
A was extracted using mild acid hydrolysis method.[46] The processed
samples for metabolomics, proteomics, membrane lipidomics, and lipid
A profiling were analyzed by liquid chromatography—mass spectrome-
try (LC–MS) at Monash Proteomics and Metabolomics Facility (Clayton,
Australia) (Experimental Section, Supporting Information).
Data Processing and Bioinformatic Analysis: Previous methods were
employed for processing DNA/RNA-Seq, lipidomics, and metabolomics
raw data.[46,47] Differential expression analysis on the normalized count
data was performed using the limma R package.[48] Gene expression lev-
els were considered significantly different across groups if the fold change
(FC) was ≥ 2 and a false discovery rate (FDR)-adjusted P value was
≤ 0.05. Genes with FC < 2 but FDR-adjusted P ≤ 0.05 were also exam-
ined. Proteomics raw data were analyzed using MaxQuant to obtain pro-
tein identifications and their respective label-free intensity.[49] The inten-
sity of metabolites and proteins was log2 transformed. Membrane phos-
pholipids were quantified based on previous methods with calibration
curves of PG, PE, and CL standards (Experimental Section, Supporting
Information).[50] The differentially abundant metabolites were identified
using one-way analysis of variance (ANOVA, two-tail), with FC ≥ 2 and
FDR-adjusted P ≤ 0.05. Principal component analysis (PCA) was con-
ducted in R.
Molecular Dynamics Simulations: All molecular dynamics simulations
were implemented using GROMACS 5.1.2.[51] The LPS-depleted, symmet-
ric OM was constructed by CELLmicrocosmos 2.2 MembraneEditor based
on the membrane lipidomics results (Dataset S4, Supporting Information)
with the reported phospholipids topology.[52,53] All membrane systems
were solvated with SPC (simple point-charge) water molecules, and the
water molecules within the membrane bilayer were removed. The topol-
ogy of colistin A and PMBN were created in PRODRG server.[54] Molecu-
lar dynamics simulations were performed for i) 5075D OM only (n = 2),
ii) 5075D OM with colistin (n = 2), iii) 5075D OM with PMBN (n = 2),
iv) 19606R OM in the absence and presence of colistin (n = 1), v) LPS-
deficient OM with a varying PG composition (20–50%) in the absence and
presence of colistin (n = 1), vi) 5075S OM (n = 1), vii) 5075D OM with
linear polymyxin B1 (n = 1), and viii) 5075D OM with linear poly-l-arginine
(n = 1) (Table S3, Supporting Information); each simulation required
≈40 h. In system v) the CL composition was fixed to 15%, while PE con-
tent varied along with PG to make the total percentage 100%; and in sys-
tem vi) the lipid A accounted for 75% of the outer leaflet of OM. For each
simulation, four polymyxin molecules were placed above the membrane
surface at random positions. Energy minimization was first conducted to
relieve unfavorable contacts in the system, followed by 1 ns equilibration
in isothermal-isovolumetric ensemble and 5 ns in isothermal-isobaric en-
semble; then a 100 ns production run was performed with the tempera-
ture maintained at 300 K using the Nose–hoover algorithm,[55] and pres-
sure maintained at 1 bar using semi-isotropic pressure coupling with the
Parrinello–Rhaman barostat.[56] All simulations were conducted using the
Australian National Computation Infrastructure and High-Performance
Computation Cluster at Shandong University (Jinan, China).
Statistical Analyses: Unless otherwise stated, all statistical analyses
were performed using R with one-way ANOVA (two-tail) or limma package
when appropriate.[48] For ANOVA analyses, Fisher’s least significant dif-
ference (LSD) post-hoc tests were used. Benjamini–Hochberg procedure
was used to adjust P-values in multiple tests. Unless otherwise stated, all
data show the mean and standard deviation (SD).
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Supporting Information is available from the Wiley Online Library or from
the author.
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